Cargando…
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical settings, occurs in several initial responders. Currently, new...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693946/ https://www.ncbi.nlm.nih.gov/pubmed/37963454 http://dx.doi.org/10.1111/1759-7714.15157 |
_version_ | 1785153268975927296 |
---|---|
author | Huang, Dingzhi Lin, Gen Chu, Qian Hu, Yi Wang, Jun Wang, Zhijie Yang, Fan Zhong, Wenzhao Zhou, Chengzhi Zhu, Bo Ai, Xinghao Cao, Baoshan Cao, Yabing Chen, Mingqiu Chen, Xiaohui Chu, Tianqing Duan, Jianchun Fan, Yun Fang, Yong Feng, Shuitu Feng, Weineng Guo, Hui Han, Chengbo He, Yong Hong, Shaodong Hu, Jie Huang, Meijuan Huang, Yan Jiang, Da Jiang, Kan Jiang, Richeng Jin, Bo Jin, Shi Li, Jisheng Li, Min Li, Ziming Li, Chao Lin, Jie Liu, Anwen Liu, Si‐Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Lu, Yuping Lv, Tangfeng Ma, Zhiyong Miao, Qian Peng, Min Pu, Xingxiang Ren, Xiu Bao Shan, Jianzhen Shan, Jinlu Shen, Peng Shen, Bo Shi, Meiqi Song, Yong Song, Zhengbo Su, ChunXia Sun, Jianguo Tian, Panwen Wang, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wu, Lin Wu, Fang Xia, Yang Xie, Congying Xie, Conghua Xin, Tao Xiong, Jianping Xu, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Yan, Xiaolong Yang, Zhenzhou Yao, Wenxiu Yu, Yao Feng, Ye Yu, Zongyang Yu, Yongfeng Yue, Dongsheng Zhang, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhao, Jun Zhao, Mingfang Zheng, Xiaobin Zhong, Fengqiao Zhou, Jin Zhou, Penghui Zhu, Zhengfei Zou, Juntao Zou, Zihua |
author_facet | Huang, Dingzhi Lin, Gen Chu, Qian Hu, Yi Wang, Jun Wang, Zhijie Yang, Fan Zhong, Wenzhao Zhou, Chengzhi Zhu, Bo Ai, Xinghao Cao, Baoshan Cao, Yabing Chen, Mingqiu Chen, Xiaohui Chu, Tianqing Duan, Jianchun Fan, Yun Fang, Yong Feng, Shuitu Feng, Weineng Guo, Hui Han, Chengbo He, Yong Hong, Shaodong Hu, Jie Huang, Meijuan Huang, Yan Jiang, Da Jiang, Kan Jiang, Richeng Jin, Bo Jin, Shi Li, Jisheng Li, Min Li, Ziming Li, Chao Lin, Jie Liu, Anwen Liu, Si‐Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Lu, Yuping Lv, Tangfeng Ma, Zhiyong Miao, Qian Peng, Min Pu, Xingxiang Ren, Xiu Bao Shan, Jianzhen Shan, Jinlu Shen, Peng Shen, Bo Shi, Meiqi Song, Yong Song, Zhengbo Su, ChunXia Sun, Jianguo Tian, Panwen Wang, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wu, Lin Wu, Fang Xia, Yang Xie, Congying Xie, Conghua Xin, Tao Xiong, Jianping Xu, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Yan, Xiaolong Yang, Zhenzhou Yao, Wenxiu Yu, Yao Feng, Ye Yu, Zongyang Yu, Yongfeng Yue, Dongsheng Zhang, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhao, Jun Zhao, Mingfang Zheng, Xiaobin Zhong, Fengqiao Zhou, Jin Zhou, Penghui Zhu, Zhengfei Zou, Juntao Zou, Zihua |
author_sort | Huang, Dingzhi |
collection | PubMed |
description | Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical settings, occurs in several initial responders. Currently, new treatment approaches have been extensively evaluated in investigational studies for these patients to tackle this difficult problem; however, the lack of consistency in clinical definition, uniform criteria for enrollment in clinical trials, and interpretation of results remain significant hurdles to progress. Thus, our expert panel comprehensively synthesized data from current studies to propose a practical clinical definition of secondary resistance to immunotherapy in NSCLC in metastatic and neoadjuvant settings. In addition to patients who received IO alone (including IO‐IO combinations), we also generated a definition for patients treated with chemotherapy plus IO. This consensus aimed to provide guidance for clinical trial design and facilitate future discussions with investigators. It should be noted that additional updates in this consensus are required when new data is available. |
format | Online Article Text |
id | pubmed-10693946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-106939462023-12-04 Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer Huang, Dingzhi Lin, Gen Chu, Qian Hu, Yi Wang, Jun Wang, Zhijie Yang, Fan Zhong, Wenzhao Zhou, Chengzhi Zhu, Bo Ai, Xinghao Cao, Baoshan Cao, Yabing Chen, Mingqiu Chen, Xiaohui Chu, Tianqing Duan, Jianchun Fan, Yun Fang, Yong Feng, Shuitu Feng, Weineng Guo, Hui Han, Chengbo He, Yong Hong, Shaodong Hu, Jie Huang, Meijuan Huang, Yan Jiang, Da Jiang, Kan Jiang, Richeng Jin, Bo Jin, Shi Li, Jisheng Li, Min Li, Ziming Li, Chao Lin, Jie Liu, Anwen Liu, Si‐Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Lu, Yuping Lv, Tangfeng Ma, Zhiyong Miao, Qian Peng, Min Pu, Xingxiang Ren, Xiu Bao Shan, Jianzhen Shan, Jinlu Shen, Peng Shen, Bo Shi, Meiqi Song, Yong Song, Zhengbo Su, ChunXia Sun, Jianguo Tian, Panwen Wang, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wu, Lin Wu, Fang Xia, Yang Xie, Congying Xie, Conghua Xin, Tao Xiong, Jianping Xu, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Yan, Xiaolong Yang, Zhenzhou Yao, Wenxiu Yu, Yao Feng, Ye Yu, Zongyang Yu, Yongfeng Yue, Dongsheng Zhang, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhao, Jun Zhao, Mingfang Zheng, Xiaobin Zhong, Fengqiao Zhou, Jin Zhou, Penghui Zhu, Zhengfei Zou, Juntao Zou, Zihua Thorac Cancer Clinical Guideline Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical settings, occurs in several initial responders. Currently, new treatment approaches have been extensively evaluated in investigational studies for these patients to tackle this difficult problem; however, the lack of consistency in clinical definition, uniform criteria for enrollment in clinical trials, and interpretation of results remain significant hurdles to progress. Thus, our expert panel comprehensively synthesized data from current studies to propose a practical clinical definition of secondary resistance to immunotherapy in NSCLC in metastatic and neoadjuvant settings. In addition to patients who received IO alone (including IO‐IO combinations), we also generated a definition for patients treated with chemotherapy plus IO. This consensus aimed to provide guidance for clinical trial design and facilitate future discussions with investigators. It should be noted that additional updates in this consensus are required when new data is available. John Wiley & Sons Australia, Ltd 2023-11-14 /pmc/articles/PMC10693946/ /pubmed/37963454 http://dx.doi.org/10.1111/1759-7714.15157 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Guideline Huang, Dingzhi Lin, Gen Chu, Qian Hu, Yi Wang, Jun Wang, Zhijie Yang, Fan Zhong, Wenzhao Zhou, Chengzhi Zhu, Bo Ai, Xinghao Cao, Baoshan Cao, Yabing Chen, Mingqiu Chen, Xiaohui Chu, Tianqing Duan, Jianchun Fan, Yun Fang, Yong Feng, Shuitu Feng, Weineng Guo, Hui Han, Chengbo He, Yong Hong, Shaodong Hu, Jie Huang, Meijuan Huang, Yan Jiang, Da Jiang, Kan Jiang, Richeng Jin, Bo Jin, Shi Li, Jisheng Li, Min Li, Ziming Li, Chao Lin, Jie Liu, Anwen Liu, Si‐Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Lu, Yuping Lv, Tangfeng Ma, Zhiyong Miao, Qian Peng, Min Pu, Xingxiang Ren, Xiu Bao Shan, Jianzhen Shan, Jinlu Shen, Peng Shen, Bo Shi, Meiqi Song, Yong Song, Zhengbo Su, ChunXia Sun, Jianguo Tian, Panwen Wang, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wu, Lin Wu, Fang Xia, Yang Xie, Congying Xie, Conghua Xin, Tao Xiong, Jianping Xu, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Yan, Xiaolong Yang, Zhenzhou Yao, Wenxiu Yu, Yao Feng, Ye Yu, Zongyang Yu, Yongfeng Yue, Dongsheng Zhang, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhao, Jun Zhao, Mingfang Zheng, Xiaobin Zhong, Fengqiao Zhou, Jin Zhou, Penghui Zhu, Zhengfei Zou, Juntao Zou, Zihua Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer |
title | Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer |
title_full | Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer |
title_fullStr | Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer |
title_full_unstemmed | Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer |
title_short | Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer |
title_sort | clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer |
topic | Clinical Guideline |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693946/ https://www.ncbi.nlm.nih.gov/pubmed/37963454 http://dx.doi.org/10.1111/1759-7714.15157 |
work_keys_str_mv | AT huangdingzhi clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT lingen clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT chuqian clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT huyi clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wangjun clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wangzhijie clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT yangfan clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhongwenzhao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhouchengzhi clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhubo clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT aixinghao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT caobaoshan clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT caoyabing clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT chenmingqiu clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT chenxiaohui clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT chutianqing clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT duanjianchun clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT fanyun clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT fangyong clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT fengshuitu clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT fengweineng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT guohui clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT hanchengbo clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT heyong clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT hongshaodong clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT hujie clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT huangmeijuan clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT huangyan clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT jiangda clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT jiangkan clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT jiangricheng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT jinbo clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT jinshi clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT lijisheng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT limin clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liziming clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT lichao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT linjie clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liuanwen clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liusiyangmaggie clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liuyutao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liuzhefeng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liuzhe clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liuzhenhua clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liuzhentian clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT liuzhigang clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT luyuping clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT lvtangfeng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT mazhiyong clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT miaoqian clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT pengmin clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT puxingxiang clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT renxiubao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT shanjianzhen clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT shanjinlu clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT shenpeng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT shenbo clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT shimeiqi clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT songyong clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT songzhengbo clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT suchunxia clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT sunjianguo clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT tianpanwen clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wangjinliang clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wangfeng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wanghuijuan clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wangjialei clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wangqian clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wangwenxian clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wangyan clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wulin clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT wufang clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xiayang clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xiecongying clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xieconghua clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xintao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xiongjianping clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xuhaipeng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xusong clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xuyiquan clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xubin clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT xuchunwei clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT yanxiaolong clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT yangzhenzhou clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT yaowenxiu clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT yuyao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT fengye clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT yuzongyang clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT yuyongfeng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT yuedongsheng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhanghaibo clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhanghongmei clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhangli clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhanglongfeng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhangqiuyu clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhangtongmei clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhangbicheng clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhaojun clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhaomingfang clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhengxiaobin clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhongfengqiao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhoujin clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhoupenghui clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zhuzhengfei clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zoujuntao clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer AT zouzihua clinicaldefinitionofsecondaryresistancetoimmunotherapyinnonsmallcelllungcancer |